Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Congo Ebola cases rise as outbreak widens

    June 19, 2026

    China activates flood response across five provinces

    June 19, 2026

    Portugal attack stalls in DR Congo World Cup draw

    June 18, 2026
    • Home
    • Contact Us
    Suez PostSuez Post
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Suez PostSuez Post
    Home » OKRA.ai, an Envision Pharma Group Company, Appoints Dr. Yahya Anvar to Senior Leadership Position
    ACCESS Newswire

    OKRA.ai, an Envision Pharma Group Company, Appoints Dr. Yahya Anvar to Senior Leadership Position

    June 15, 2023
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    PHILADELPHIA, PA / ACCESSWIRE / June 15, 2023 / OKRA.ai, an Envision Pharma Group (Envision) company, has appointed senior leader Dr. Yahya Anvar as Chief of AI Science & Insights to unleash the full potential of artificial intelligence (AI) and to further support the life sciences industry.

    Envision Pharma Group, Thursday, June 15, 2023, Press release picture

    “I am excited about continuing the innovative collaboration between Envision and OKRA.ai along with Yahya as a senior leader as it further solidifies our Envision commitment to the expansion of OKRA.ai and leadership in the AI and technical space,” shares Meg Heim, CEO of Envision Pharma Group. “His leadership is critical to our vision to accelerate the delivery of our compelling combination of technology-enabled capabilities and solutions to clients as we continue to strengthen our offerings across the product life cycle, but more importantly to support patients in their journey to health and wellness.”

    Anvar joined OKRA.ai in 2019, heading the Data Science team. During his tenure, he has led the development of AI solutions across OKRA.ai’s portfolio of products and services. Prior to joining the company, he served as the principal investigator of preclinical personalized medicine at Leiden University Medical Center. He has over 14 years of experience in the healthcare sector and is the author of over 30 peer-reviewed scientific articles. Anvar holds a PhD in Computational Biology from the faculty of Medicine at Leiden University, and an MSc in Bioinformatics and Artificial Intelligence from Brunel University.

    Anvar shares, “It is an absolute privilege to be leading the AI insights and science at Envision and pushing the boundaries of what AI has to offer to better patients’ outcomes. Making an impact through solutions that provide actionable, explainable insights is what we thrive for. There is no better time for new beginnings than today, and I’m so excited to be working with the Envision team to transform the industry as we know it.”

    Dr. Loubna Bouarfa, Head of AI & Innovative Platforms at Envision, shares, “It was a pleasure to work with Yahya; he has been an exceptional leader of the Data Science team at OKRA.ai. His role has now expanded to cover AI insights and scientific expertise across the entire Envision organization following our recent acquisition. I look forward to working with him in driving AI innovation and propelling Envision to new heights.”

    About Envision Pharma Group

    Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 18 of the top 20 pharmaceutical companies. Envision supports clients across the product life cycle through a comprehensive suite of services and industry-leading technology solutions that include artificial intelligence and natural language processing, commercialization and integrated strategic consulting, evidence-based scientific communications and engagement, HEOR/market access and data analytics, medical capabilities, and omnichannel solutions. Learn more at www.envisionpharmagroup.com.

    Contact Information:

    Colleen Carter
    Associate Director, Communications, Office of CEO
    colleen.carter@envisionpharma.com
    1 (508) 505 8856

    SOURCE: Envision Pharma Group

    .

    Related Posts

    Ostathi, Operated by UniHouse, Pioneers the Middle East’s First Digital Infrastructure Linking Structured Workforce Development to Verified Income

    May 7, 2026

    ZOQQ Approaches Breakeven on a Bootstrapped Path – Bucking the Burn-First Fintech Playbook

    May 4, 2026

    Datavault AI Further Expands IP Portfolio with New Patent Issuance and Notices of Allowance

    April 22, 2026

    Datavault AI Announces Upcoming Listing of Meme Coin Portfolio and Institutional RWA Token Suite on the Biconomy Exchange

    April 13, 2026

    Datavault AI Inc. (NASDAQ: DVLT) Announces $750 Million in Tokenization Contracts Signed in Q1 2026, Generating $77 Million in Associated Fees

    April 8, 2026

    Datavault AI CEO Nathaniel Bradley to Present DataValue(R), DataScore(R), and Information Data Exchange(R) Technologies at XRP Tokyo 2026

    April 2, 2026
    Recent News

    Congo Ebola cases rise as outbreak widens

    June 19, 2026

    China activates flood response across five provinces

    June 19, 2026

    Portugal attack stalls in DR Congo World Cup draw

    June 18, 2026

    DWTC and -45dB launch modular meeting spaces in Dubai

    June 18, 2026

    UAE and Egypt presidents discuss ties at G7 summit

    June 18, 2026

    Japan core machinery orders rebound 8.7% in April

    June 18, 2026

    Emirates launches expanded travel insurance for global trips

    June 18, 2026

    France opens World Cup with 3-1 win over Senegal

    June 17, 2026
    © 2026 Suez Post | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.